James Mond's most recent trade in Adma Biologics Inc was a trade of 139,000 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 25, 2021.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adma Biologics Inc | James Mond | EVP, CSO and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 139,000 | 139,000 | - | - | Employee Stock Option (right to buy) | |
| Adma Biologics Inc | James Mond | EVP, CSO and CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 64,361 | 137,535 (0%) | 0% | 0 | Common Stock | |
| Adma Biologics Inc | James Mond | EVP, CSO and CMO | Purchase of securities on an exchange or from another person at price $ 2.20 per share. | 08 Sep 2020 | 4,000 | 73,174 (0%) | 0% | 2.2 | 8,800 | Common Stock |
| Adma Biologics Inc | James Mond | EVP, CSO and CMO | Purchase of securities on an exchange or from another person at price $ 2.88 per share. | 10 Aug 2020 | 5,000 | 67,174 (0%) | 0% | 2.9 | 14,400 | Common Stock |
| Adma Biologics Inc | James Mond | EVP, CSO and CMO | Purchase of securities on an exchange or from another person at price $ 2.88 per share. | 10 Aug 2020 | 2,000 | 69,174 (0%) | 0% | 2.9 | 5,750 | Common Stock |